Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

The French Endocrine Society suggests diagnosing PCOS with two of three signs, recommends lifestyle changes and clomiphene for treatment, and calls for more research on certain treatments and tests.

Prenatal antiandrogen treatment altered hormone levels in adult spotted hyenas, affecting males and females differently.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

Some medicines can reduce excessive hair growth in women, but more research is needed to compare treatments and consider side effects.

Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.

Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.

Hormonal treatments can improve acne, but they come with potential side effects and risks.

Hormonal treatment is effective for women with acne not helped by usual treatments, especially if they have hormonal imbalances.

The nafarelin test can reliably distinguish between gonadotropin deficiency and delayed puberty in teenage boys.

Most women with too much androgens have PCOS, which can be managed with birth control pills, medication for hair growth, and fertility treatments, and losing weight helps too.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

PCOS treatment focuses on inducing ovulation, reducing androgens, and managing long-term health risks with medications and lifestyle changes.

Early medical support for transgender youth is important for their health, with low regret for gender-affirming hormone use and a need for knowledgeable care providers.

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

Hirsutism in women often indicates a hormonal imbalance and can be managed with a combination of hormonal treatments and hair removal methods.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

Both finasteride and GnRH agonist treatments reduced hair growth in women with idiopathic hirsutism, but GnRH agonist was more effective.

Medical castration in prostate cancer patients can increase the risk of serious heart rhythm problems, so it's important to monitor heart activity during treatment.

Low prolactin levels in PCOS can cause metabolic problems like insulin resistance and obesity.

Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.

Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.

Male hormones and their interactions are crucial for male sexual development and characteristics.

The document concludes that treatment for excessive hair growth depends on the cause, with options including hair removal methods and medications like anti-androgens or insulin-sensitizing drugs.

Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.

Polycystic Ovary Syndrome (PCOS) often leads to severe acne, and lifestyle changes and hormonal treatments can help manage it.

The document concludes that hirsutism can be managed with various treatments tailored to the individual, potentially improving quality of life.

Microglia, the brain's immune cells, may contribute to Polycystic Ovary Syndrome (PCOS) by altering the female brain's structure and function, with kisspeptin neurons and GABA neurotransmitters also playing a role.

Dihydrotestosterone changes some hormone-related gene expressions in rat pituitary glands but doesn't affect the estrous cycle.